Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions

Tsai, Hao-Yuan; Wu, Yen‐Wen; Tseng, Wei‐Kung; Leu, Hsin‐Bang; Yin, Wei-Hsian; Lin, Tsung‐Hsien; Chang, Kuan-Cheng; Wang, Ji‐Hung; Yeh, Hung‐I; Wu, Chau‐Chung; Chen, Jaw-Wen

doi:10.1016/j.jfma.2020.08.007

Cited by 10 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study provides information about the signi cant positive association between FABP4 and BPS(r =0.366, P = 0.004), as has previously been reported [53,54]. We could not nd a signi cant association between plasma FABP4 and FBS in our RA patients and healthy subjects, but a recent study conducted by Valéria et al demonstrates that FABP4 is involved in some aspects of the metabolic syndrome, including the establishment of type 2 diabetes [55].…”

Section: Discussionsupporting

confidence: 66%

FABP4 and S100A12, a notable link between inflammatory mediators and cardiovascular risk in rheumatoid arthritis

khoobbakht,

Roghani,

Soufivand

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: 50% of the deaths of RA patients are due to cardiovascular diseases, and inflammation plays an important role in its pathogenesis. FABP4 and S100A12 are involved as inflammatory mediators in the pathogenesis of CVD. For the first time, in a recent study, we evaluated the association between FABP4 and S100A12 plasma concentrations with cardiovascular risk factors in RA patients. Material and methods: 60 patients with RA (30 newly diagnosed and 30 under treatment) and 30 healthy individuals participated in this study with their personal consent. FABP4 and S100A12 plasma concentrations were measured by ELISA (enzyme-linked immunosorbent assay) method. Using ADVIA 1800 Clinical Chemistry System based on latex-enhanced immunoturbidimetric, HS-CRP concentration was calculated. Results: The FABP4 plasma concentration was significantly elevated in the newly diagnosed and under-treatment RA patients compared to healthy subjects (P <0.001 and P = 0.008, respectively). The plasma levels of S100A12 were remarkably higher in the new case compared to the control groups (P =0.001).There was a significantly positive association between the FABP4 and S100A12 with NT-proBNP(r =0.493, P < 0.001; r =0.445, P < 0.001, respectively). Conclusion: FABP4 and S100A12 correlate with cardiovascular biomarkers in RA patients.

show abstract

Section: Discussionsupporting

confidence: 66%

FABP4 and S100A12, a notable link between inflammatory mediators and cardiovascular risk in rheumatoid arthritis

khoobbakht,

Roghani,

Soufivand

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…peripheral artery disease. Moreover, hypertension, DM, increased systolic blood pressure, along with higher glucose levels have been believed to be associated with an increase in FABP4 circulating levels (Tsai et al, 2021). Finally, the authors have revealed lower serum concentration of CTRP3 in CHD patients, especially in acute MI (Si et al, 2020;Koteliukh et al, 2022).…”

Section: Resultsmentioning

confidence: 92%

Predictive model for recurrent myocardial infarction in patients with type 2 diabetes mellitus

Koteliukh¹

2022

View full text Add to dashboard Cite

Background: Recurrent myocardial infarction (MI) is one of the commonest and serious cardiovascular complications among diabetic patients. This study was planned to predict the recurrent MI development in diabetic patients using parameters of energy and adipokine metabolism. Methods: In total, 74 patients with type DM and acute MI were enrolled in the study. Measurements of serum adropin, irisin, fatty acid binding protein 4 (FABP4) and C1q/TNF related protein 3 levels were performed using enzyme-linked immunosorbent assay. The study employed generalized linear mixed models (GLMMs) to predict recurrent MI development. Results: The accuracy of predicting the absence of recurrent MI during a year in diabetic patients was 98.4%, and the accuracy of predicting the probability of recurrent MI during a year in diabetic patients was 92.3%. The global model accuracy was 97.3%. Conclusions:GLMM has shown that the levels of irisin on day 14, insulin on day 1 and the combined effect of blood glucose on days 1 and 14 were negative prognostic factors. The total impact of FABP4 on day 1, HOMA-IR on day 1 and adropin on day 14 had a positive prognostic value.

show abstract

“…Other studies show association of FABP4 levels with elongated QT intervals in patients with stable angina and kidney disease [ 65 ], but also with rapid renal functional decline in patients with diabetes [ 66 ]. A study of 973 patients undergoing coronary intervention shows FABP4 associated with cardiovascular outcome [ 67 ]. In type 2 diabetes patients, FABP4 levels were positively associated with peripheral artery disease [ 68 ], similar to a study involving hemodialysis patients [ 69 ].…”

Section: Observational Studies Of Fabp4mentioning

confidence: 99%

The Effects of FABP4 on Cardiovascular Disease in the Aging Population

van der Ark-Vonk,

Puijk,

Pasterkamp

et al. 2024

Curr Atheroscler Rep

View full text Add to dashboard Cite

Purpose of Review Fatty acid-binding protein 4 (FABP4) plays a role in lipid metabolism and cardiovascular health. In this paper, we cover FABP4 biology, its implications in atherosclerosis from observational studies, genetic factors affecting FABP4 serum levels, and ongoing drug development to target FABP4 and offer insights into future FABP4 research. Recent Findings FABP4 impacts cells through JAK2/STAT2 and c-kit pathways, increasing inflammatory and adhesion-related proteins. In addition, FABP4 induces angiogenesis and vascular smooth muscle cell proliferation and migration. FABP4 is established as a reliable predictive biomarker for cardiovascular disease in specific at-risk groups. Genetic studies robustly link PPARG and FABP4 variants to FABP4 serum levels. Considering the potential effects on atherosclerotic lesion development, drug discovery programs have been initiated in search for potent inhibitors of FABP4. Summary Elevated FABP4 levels indicate an increased cardiovascular risk and is causally related to acceleration of atherosclerotic disease, However, clinical trials for FABP4 inhibition are lacking, possibly due to concerns about available compounds’ side effects. Further research on FABP4 genetics and its putative causal role in cardiovascular disease is needed, particularly in aging subgroups.

show abstract

Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions

Cited by 10 publications

References 43 publications

FABP4 and S100A12, a notable link between inflammatory mediators and cardiovascular risk in rheumatoid arthritis

FABP4 and S100A12, a notable link between inflammatory mediators and cardiovascular risk in rheumatoid arthritis

Predictive model for recurrent myocardial infarction in patients with type 2 diabetes mellitus

The Effects of FABP4 on Cardiovascular Disease in the Aging Population

Contact Info

Product

Resources

About